RecruitingAcute Myeloid LeukemiaAcute Lymphoblastic LeukemiaHodgkin Lymphoma

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

Eligible age

0.6–21 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in the post-transplant period to treat pediatric patients with relapsed or refractory hematologic malignancies or high risk solid tumors.

Sponsor: University of Wisconsin, Madison

You may qualify if…

✓ Availability of an eligible haploidentical donor
✓ Hematologic malignancy or solid tumor
✓ Patients with more than one malignancy (hematologic or solid tumor) are eligible
✓ Patients with hematologic malignancy must have no HLA identical sibling or suitable unrelated donor OR time needed to find an acceptable unrelated donor match would likely result in disease progression such that the patient may become ineligible for any type of potentially curative transplant
✓ Relapsed or primary therapy-refractory AML with bone marrow blast \< 20%
✓ High-risk refractory or relapsed ALL in patients for whom transplantation is deemed indicated (relapse occurring \< 30 months from diagnosis, patients relapsing after previous allogeneic transplant, relapse after 2nd remission, primary induction failure or hypodiploidy)
✓ Relapsed Hodgkin lymphoma unable to achieve 2nd remission or Very Good Partial Response (VGPR) and therefore ineligible to receive autologous hematopoietic stem cell transplant (auto-HSCT)
✓ Hodgkin lymphoma relapsing after auto-HSCT

You may not qualify if…

✕ Pregnant or breast-feeding
✕ HIV infection
✕ Heart failure or uncontrolled cardiac rhythm disturbance
✕ Uncontrolled, Serious Active Infection
✕ Prior organ allograft
✕ Significant serious intercurrent illness unrelated to cancer or its treatment not covered by other exclusion criteria expected to significantly increase the risk of HSCT
✕ Any mental or physical condition, in the opinion of the PI (or PI designee), which could interfere with the ability of the subject (or the only parent or legal guardian available to care for the subject) to understand or adhere to the requirements of the study
✕ Enrollment in any other clinical study from screening up to Day 100 (unless PI judges such enrollment would not interfere with endpoints of this study)

Where it's recruiting

Wisconsin

Madison

Source: ClinicalTrials.gov · NCT02508038 · last updated 2025-10-16